```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
VAR G1=O/S
VAR G2=CY/11
VAR G3=1/5
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE


=> s l1 ful
FULL SEARCH INITIATED 14:47:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  53400 TO ITERATE

100.0% PROCESSED   53400 ITERATIONS                                42 ANSWERS
SEARCH TIME: 00.00.02

L3            42 SEA SSS FUL L1
```

AN 2000:420959 CAPLUS
DN 133:43441
TI Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Gardner, Daniel S.
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 327 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035449	A1	20000622	WO 1999-US30292	19991217
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1156807	A1	20011128	EP 1999-968144	19991217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6331541	B1	20011218	US 1999-465288	19991217
	TR 200101859	T2	20011221	TR 2001-20010185919991217	
	ZA 2001003756	A	20020509	ZA 2001-3756	20010509
	US 2003013741	A1	20030116	US 2001-7172	20011023
	US 6521592	B2	20030218		
	US 2004002515	A1	20040101	US 2002-279416	20021024
	US 2004006107	A1	20040108	US 2002-279231	20021024
PRAI	US 1998-112717P	P	19981218		
	US 1999-161221P	P	19991022		
	US 1999-161137P	P	19991022		
	US 1999-161184P	P	19991022		
	US 1999-161222P	P	19991022		
	US 1999-465287	A3	19991217		
	US 1999-465288	A3	19991217		
	US 1999-465948	A3	19991217		
	WO 1999-US30292	W	19991217		

OS MARPAT 133:43441
GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3,

CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

IT **275810-34-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275810-34-9 CAPLUS

CN Urea, N-[3-[3-[(4-fluorophenyl)methyl]-1-pyrrolidinyl]propyl]-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

> d bib abs 1-9

L14 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:622568 CAPLUS
DN 139:164710
TI Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.
IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.
PA Bristol-Myers Squibb Pharma Company, USA
SO U.S., 145 pp., Cont.-in-part of U.S. Ser. No. 465,286, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6605623	B1	20030812	US 2000-598821	20000621
	US 6331541	B1	20011218	US 1999-465288	19991217
	ZA 2001003756	A	20020509	ZA 2001-3756	20010509
	WO 2001098269	A2	20011227	WO 2001-US19745	20010620
	WO 2001098269	A3	20030710		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1363881	A2	20031126	EP 2001-950358	20010620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2004517803	T2	20040617	JP 2002-504225	20010620
	US 2003013741	A1	20030116	US 2001-7172	20011023
	US 6521592	B2	20030218		
	US 2004002515	A1	20040101	US 2002-279416	20021024
	US 2004006107	A1	20040108	US 2002-279231	20021024
	US 2004058960	A1	20040325	US 2003-465191	20030619
PRAI	US 1998-112717P	P	19981218		
	US 1999-161243P	P	19991022		
	US 1999-465286	B2	19991217		
	US 1999-161137P	P	19991022		
	US 1999-161184P	P	19991022		
	US 1999-161222P	P	19991022		
	US 1999-465287	A3	19991217		
	US 1999-465288	A3	19991217		
	US 1999-465948	A3	19991217		
	US 2000-213051P	P	20000621		
	US 2000-598821	A	20000621		
	WO 2001-US19745	W	20010620		

OS MARPAT 139:164710
GI



I

AB [Title compds. I; M = CH2, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, L = CH2, CHR5, CHR6, CR6R6, CR5R6; Z = O, S; M = CH2, CHR5, CHR13, CR13R13, CR5R13; K = CHR5, CR5R6; Z = O, S; E = (CHR7)(CHR9)v(CR11R12); R1, R2 = H, alkyl, alkenyl, alkynyl, (substituted) alkylcycloalkyl; R2R3 = atoms to form a (substituted) 5-7 membered ring; R3, R5 = (substituted) (alkyl)cycloalkyl, (alkyl)heterocyclyl; R4 = null, O, alkyl, alkenyl, alkynyl, etc.; R4 with R7, R9, or R11 = atoms to form a 5-7 membered ring; R6 = alkyl, alkenyl, alkynyl, etc.; R7, R9 = H; R4R7, R4R9 = (substituted) spirocyclyl; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R11R12 = pyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydropyranyl; v = 1, 2], were prepared as modulators of chemokine activity (no data) for preventing asthma and other allergic diseases. Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) in THF was treated with 3-cyanophenyl isocyanate to give N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. A pharmaceutical composition comprising the compound I was claimed.

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:150534 CAPLUS
DN 138:204946
TI Preparation of N-ureidoalkylpiperidines as modulators of CCR3 chemokine receptor activity for the prevention of asthma and other allergic diseases
IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Wacker, Dean A.; Zheng, Changsheng
PA Bristol-Myers Squibb Pharma Company, USA
SO U.S., 126 pp., Cont.-in-part of U.S. Ser. No. 466,442.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6525069	B1	20030225	US 2000-597400	20000621
	US 6331541	B1	20011218	US 1999-465288	19991217
	US 6444686	B1	20020903	US 1999-466442	19991217
	ZA 2001003756	A	20020509	ZA 2001-3756	20010509
	WO 2001098270	A2	20011227	WO 2001-US19752	20010620
	WO 2001098270	A3	20020530		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1294690	A2	20030326	EP 2001-950360	20010620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004516238	T2	20040603	JP 2002-504226	20010620
	US 2003013741	A1	20030116	US 2001-7172	20011023
	US 6521592	B2	20030218		
	US 2003114489	A1	20030619	US 2002-180869	20020626
	US 2004002515	A1	20040101	US 2002-279416	20021024
	US 2004006107	A1	20040108	US 2002-279231	20021024
	US 2004034063	A1	20040219	US 2003-359443	20030206
PRAI	US 1998-112717P	P	19981218		
	US 1999-161221P	P	19991022		
	US 1999-466442	A2	19991217		
	US 1999-161137P	P	19991022		
	US 1999-161184P	P	19991022		

US 1999-161222P P 19991022
US 1999-465287 A3 19991217
US 1999-465288 A3 19991217
US 1999-465948 A3 19991217
US 2000-213208P P 20000621
US 2000-597400 A 20000621
WO 2001-US19752 W 20010620
OS MARPAT 138:204946
GI



I

AB Title compds. [I; M, Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, K, L = CH2, CHR5, CHR6, CR6R6, CR5R6; ≥1 of J, K, L contains R5; Z = O, S, NR1a, CHCN, CHNO2, C(CN)2; R1a = H, alkyl, cycloalkyl, CN, NO2, etc.; E = (substituted) C3-6 carbocyclyl, methylenecarbocyclyl, ethylenecarbocyclyl, etc.; R1, R2 = H, alkyl, alkenyl, alkynyl; R3 = (substituted) alkyl, alkenyl, alkynyl; R4 = null, N-oxide, alkyl, alkenyl, alkynyl, cycloalkylalkyl, etc.; R5 = (substituted) alkylenecarbocyclyl, alkyleneheterocyclyl; R6 = alkyl, alkenyl, alkynyl, alkylcycloalkyl, perfluoroalkyl, hydroxyalkyl, mercaptoalkyl, aminoalkyl, CN, etc.; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, mercaptoalkyl, acylaminoalkyl, (substituted) phenylalkyl, etc.], were prepared as CCR3 modulators (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) and 3-cyanophenyl isocyanate were stirred 30 min. in THF to give N-3-cyanophenyl-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea.
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:935575 CAPLUS
DN 136:69739
TI Preparation of piperidinoalkylureas as chemokine receptor modulators
IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Wacker, Dean A.; Zheng, Changsheng
PA Dupont Pharmaceuticals Company, USA
SO PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001098270	A2	20011227	WO 2001-US19752	20010620
WO 2001098270	A3	20020530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	US 6525069	B1	20030225	US 2000-597400	20000621
	EP 1294690	A2	20030326	EP 2001-950360	20010620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004516238	T2	20040603	JP 2002-504226	20010620
PRAI	US 2000-213208P	P	20000621		
	US 2000-597400	A	20000621		
	US 1998-112717P	P	19981218		
	US 1999-161221P	P	19991022		
	US 1999-466442	A2	19991217		
	WO 2001-US19752	W	20010620		

OS MARPAT 136:69739

AB The title compds. were prepared as chemokine receptor modulators (no data). Thus, PhCH2Z(CH2)3NHR (Z = piperidine-4,1-diyl)(I; R = H)(preparation given) was amidated by 3-(NC)C6H4NCO to give I [R = CONHC6H4(CN)-3].

L14 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:935574 CAPLUS

DN 136:69738

TI Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.

IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B.; Wacker, Dean A.; Yao, Wenqing

PA Dupont Pharmaceuticals Company, USA; Bristol-Myers Squibb Pharmaceutical Co.

SO PCT Int. Appl., 446 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098269	A2	20011227	WO 2001-US19745	20010620
	WO 2001098269	A3	20030710		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6605623	B1	20030812	US 2000-598821	20000621
	EP 1363881	A2	20031126	EP 2001-950358	20010620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2004517803	T2	20040617	JP 2002-504225	20010620
PRAI	US 2000-213051P	P	20000621		
	US 2000-598821	A	20000621		
	US 1998-112717P	P	19981218		
	US 1999-161243P	P	19991022		
	US 1999-465286	B2	19991217		
	WO 2001-US19745	W	20010620		

OS MARPAT 136:69738

GI



I

AB [Title compds. I; M = CH2, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, L = CH2, CHR5, CHR6, CR6R6, CR5R6; Z = O, S; M = CH2, CHR5, CHR13, CR13R13, CR5R13; K = CHR5, CR5R6; Z = O, S; E = (CHR7)(CHR9)v(CR11R12); R1, R2 = H, alkyl, alkenyl, alkynyl, (substituted) alkylcycloalkyl; R2R3 = atoms to form a (substituted) 5-7 membered ring; R3, R5 = (substituted) (alkyl)cycloalkyl, (alkyl)heterocyclyl; R4 = null, O, alkyl, alkenyl, alkynyl, etc.; R4 with R7, R9, or R11 = atoms to form a 5-7 membered ring; R7, R9 = H; R4R7, R4R9 = (substituted) spirocyclyl; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R11R12 = pyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydropyranyl; v = 1, 2], were prepared as modulators of chemokine activity (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) in THF was treated with 3-cyanophenyl isocyanate to give N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea.

L14 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:565016 CAPLUS
DN 135:137529
TI Preparation of azepine derivatives as VLA-4 antagonists
IN Ikegami, Satoru; Inoguchi, Kiyoshi; Fukui, Hideto; Sumita, Yuji; Maruyama, Tatsuya; Watanuki, Mitsuru
PA Kaken Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055121	A1	20010802	WO 2001-JP521	20010126

PI
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-20358 A 20000128
OS MARPAT 135:137529
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = H, alkyl, aryl; R2 = H, (CH3)3COCO; R3 = alkylene, divalent aromatic hydrocarbon derivs.; R4 = H, alkyl; X = aromatic hydrocarbon; heterocycle; m = 1, 2, 3; Y = N, O; Z = R8R7R6A1; A1 = CH2, SO2; R6 = alkylene, divalent arylalkane derivs.; R7 = CH2, CO; R8 = alkyl, arylalkyl] and salts are prepared Title compds. or salts of title compds. are used as the active ingredient in remedies having peroral absorbability and exhibiting VLA-4 antagonism. Thus, the title compound II was prepared and biol. tested for VLA-4 antagonism.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:420964 CAPLUS
DN 133:43445
TI Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
IN Ko, Soo S.; Duncia, John V. K.; Santella, Joseph B., III; Wacker, Dean A.; Kim, Ui Tae
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 351 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035454	A1	20000622	WO 1999-US30336	19991217
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1140087	A1	20011010	EP 1999-965322	19991217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6331541	B1	20011218	US 1999-465288	19991217
	US 6492400	B1	20021210	US 1999-465287	19991217
	ZA 2001003756	A	20020509	ZA 2001-3756	20010509
	US 2003013741	A1	20030116	US 2001-7172	20011023
	US 6521592	B2	20030218		
	US 2004002515	A1	20040101	US 2002-279416	20021024
	US 2004006107	A1	20040108	US 2002-279231	20021024
PRAI	US 1998-112717P	P	19981218		
	US 1999-161184P	P	19991022		
	US 1999-161137P	P	19991022		
	US 1999-161222P	P	19991022		
	US 1999-465287	A3	19991217		
	US 1999-465288	A3	19991217		
	US 1999-465948	A3	19991217		
	WO 1999-US30336	W	19991217		

OS MARPAT 133:43445
GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/da (oral dosage).
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:420963 CAPLUS
DN 133:43444
TI Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
IN Ko, Soo; Clark, Cheryl Mcardle; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.
PA Du Pont Pharmaceuticals Co., USA
SO PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035453	A1	20000622	WO 1999-US30335	19991217
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1158980	A1	20011205	EP 1999-965321	19991217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6331541	B1	20011218	US 1999-465288	19991217
	US 6486180	B1	20021126	US 1999-465948	19991217
	ZA 2001003756	A	20020509	ZA 2001-3756	20010509
	US 2003013741	A1	20030116	US 2001-7172	20011023
	US 6521592	B2	20030218		
	US 2004002515	A1	20040101	US 2002-279416	20021024
	US 2004006107	A1	20040108	US 2002-279231	20021024
PRAI	US 1998-112717P	P	19981218		
	US 1999-161137P	P	19991022		
	US 1999-161184P	P	19991022		
	US 1999-161222P	P	19991022		
	US 1999-465287	A3	19991217		
	US 1999-465288	A3	19991217		
	US 1999-465948	A3	19991217		
	WO 1999-US30335	W	19991217		

OS MARPAT 133:43444
GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:420962 CAPLUS
DN 133:43443
TI Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Santella, Joseph B. Iii; Wacker, Dean A. K.
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 388 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035452	A1	20000622	WO 1999-US30334	19991217
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1161240	A1	20011212	EP 1999-963107	19991217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6331541	B1	20011218	US 1999-465288	19991217
	TR 200101859	T2	20011221	TR 2001-20010185	19991217
	BR 9917038	A	20020402	BR 1999-17038	19991217
	JP 2002532427	T2	20021002	JP 2000-587772	19991217
	NZ 511394	A	20030725	NZ 1999-511394	19991217
	AU 770042	B2	20040212	AU 2000-19406	19991217
	ZA 2001003756	A	20020509	ZA 2001-3756	20010509
	NO 2001002977	A	20010820	NO 2001-2977	20010615
	US 2003013741	A1	20030116	US 2001-7172	20011023
	US 6521592	B2	20030218		

	US 2004002515	A1	20040101	US 2002-279416	20021024
	US 2004006107	A1	20040108	US 2002-279231	20021024
PRAI	US 1998-112717P	P	19981218		
	US 1999-161221P	P	19991022		
	US 1999-161137P	P	19991022		
	US 1999-161184P	P	19991022		
	US 1999-161222P	P	19991022		
	US 1999-465287	A3	19991217		
	US 1999-465288	A3	19991217		
	US 1999-465948	A3	19991217		
	WO 1999-US30334	W	19991217		

OS MARPAT 133:43443

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:420961 CAPLUS

DN 133:43442

TI Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

IN Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.; Watson, Paul S.; Varnes, Jeffrey G.

PA Du Pont Pharmaceuticals Company, USA

SO PCT Int. Appl., 394 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035451	A1	20000622	WO 1999-US30332	19991217

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,

MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 1140086 A1 20011010 EP 1999-964297 19991217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
US 6331541 B1 20011218 US 1999-465288 19991217
ZA 2001003756 A 20020509 ZA 2001-3756 20010509
US 2003013741 A1 20030116 US 2001-7172 20011023
US 6521592 B2 20030218
US 2004002515 A1 20040101 US 2002-279416 20021024
US 2004006107 A1 20040108 US 2002-279231 20021024
PRAI US 1998-112717P P 19981218
US 1999-161243P P 19991022
US 1999-161137P P 19991022
US 1999-161184P P 19991022
US 1999-161222P P 19991022
US 1999-465287 A3 19991217
US 1999-465288 A3 19991217
US 1999-465948 A3 19991217
WO 1999-US30332 W 19991217
OS MARPAT 133:43442
GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT